Sanofi Consumer Healthcare India Ltd

Net profit of Sanofi Consumer Healthcare India rose 39.78% to Rs 62.90 crore in the quarter ended September 2025 as against Rs 45.00 crore during the previous quarter ended September 2024. Sales rose 46.28% to Rs 233.90 crore in the quarter ended September 2025 as against Rs 159.90 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales233.90159.90 46 OPM %36.3439.46 - PBDT87.4063.90 37 PBT84.1062.40 35 NP62.9045.00 40 Powered by Capital Market - Live

On a standalone basis, revenue from operations stood at Rs 233.9 crore, up 46% year-on-year and 6% sequentially, driven by exports and domestic business. Domestic sales grew 20% YoY, while exports surged more than tenfold due to a low base. Profit before tax (PBT) increased 37.4% YoY to Rs 84.1 crore in Q3 CY25, and was up 6.59% sequentially. Profit after tax (PAT) came in at Rs 62.9 crore, up 40% year-on-year and 4% sequentially. On the cost side, total expenses rose 50.2% YoY to Rs 152.8 crore. Cost of materials consumed was Rs 36.5 crore, up 159% YoY, while employee expenses rose to Rs 31.7 crore, up 16% YoY. Quarter figures are not directly comparable due to the demerger and voluntary recall of certain variants of key brands in the domestic market. Managing director Himanshu Bakshi said, Our third-quarter results reflect the strength of our diversified portfolio driving sustained growth momentum this quarter. The domestic business demonstrates good performance, with exports providing additional impetus to revenue growth. All our voluntarily recalled products have successfully re-established their market presence within the year. Anchored in science and guided by purpose, we remain committed to making self-care simpler, more accessible and more effective for every consumer. Sanofi Consumer Healthcare India Limited (SCHIL) has emerged as a distinct legal entity following its demerger from Sanofi India. It now operates as an independent entity with a focused mandate in the consumer healthcare segment. Powered by Capital Market - Live

Sanofi Consumer Healthcare India will hold a meeting of the Board of Directors of the Company on 12 November 2025.Powered by Capital Market - Live

According to the company's regulatory filing, Naidu's resignation will be effective from the close of business hours on 15 October 2025, which will be his last working day with the company. Sanofi Consumer Healthcare India officially demerged from Sanofi India on 1 June 2024 and now operates as an independent entity focused solely on the consumer healthcare segment. Its key product categories include allergy care, digestive wellness, pain relief, multivitamins, and herbal/traditional supplements, with flagship brands such as Allegra, DePURA, Avil, and Combiflam anchoring its portfolio. The company reported a 28% year-on-year rise in revenue to Rs 220.9 crore in Q2 2025, powered by export operations and successful product launches. On a sequential basis, the company's revenue rose 27.5% from Rs 172.6 crore in Q1 2025. Profit after tax (PAT) for the quarter stood at Rs 60.7 crore, marking a 21% increase over Q1FY25 and a 109% surge from Rs 29 crore in Q2 2024. The scrip declined 0.84% to Rs 4,624 on the BSE.Powered by Capital Market - Live

The company reported a 28% year-on-year rise in revenue to Rs 220.9 crore in Q2 2025, powered by export operations and successful product launches. On a sequential basis, the company's revenue rose 27.5% from Rs 172.6 crore in Q1 2025. Profit after tax (PAT) for the quarter stood at Rs 60.7 crore, marking a 21% increase over Q1FY25 and a 109% surge from Rs 29 crore in Q2 2024. Profit before tax (PBT) came in at Rs 78.9 crore, up 102.83% YoY and 18.11% QoQ. While result is impressive, the company noted that financials are not strictly comparable due to the demerger and voluntary recall of certain variants of key brands. Net cash flow from operations during the half year ended 30 June 2025 stood at Rs 17.9 crore, steeply down from Rs 231.50 crore in the same period last year. Himanshu Bakshi, managing director, Sanofi Consumer Healthcare India, said: Our commitment to delivering high-quality, science-backed products continues to anchor our growth strategy-driven by a focused portfolio, research-led innovation, and an agile organization. This quarter reflects the outcomes of that focused approach, with successful relaunch of two previously recalled products and introduction of a new product. We also commenced export operations allowing us to extend our efforts towards international markets. As we look ahead, we remain steadfast in our purpose to make self-care simpler, more accessible and effective for consumers. During the half year, the company launched Allegra D, a unique proposition in the Allergy segment, also relaunched Depura 60k and Combiflam Suspension which were recalled voluntarily last year. Other legacy brands such as Avil, and Depura continue to uphold strong consumer trust and drive long-term relevance in their respective categories. Sanofi Consumer Healthcare India officially demerged from Sanofi India on 1 June 2024 and now operates as an independent entity focused solely on the consumer healthcare segment. Its key product categories include allergy care, digestive wellness, pain relief, multivitamins, and herbal/traditional supplements, with flagship brands such as Allegra, DePURA, Avil, and Combiflam anchoring its portfolio. Powered by Capital Market - Live

Net profit of Sanofi Consumer Healthcare India rose 109.31% to Rs 60.70 crore in the quarter ended June 2025 as against Rs 29.00 crore during the previous quarter ended June 2024. Sales rose 28.21% to Rs 220.90 crore in the quarter ended June 2025 as against Rs 172.30 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales220.90172.30 28 OPM %31.7836.91 - PBDT75.3064.30 17 PBT72.3063.20 14 NP60.7029.00 109 Powered by Capital Market - Live

Sanofi Consumer Healthcare India will hold a meeting of the Board of Directors of the Company on 4 August 2025.Powered by Capital Market - Live

Revenue from operations fell 22.11% YoY to Rs 172.60 crore in the quarter ended 31 March 2025. On a sequential basis, net profit rose 12.86% and revenue increased 1.11% compared to Q4 2024. During the quarter, total expenses declined 12.10% YoY to Rs 111 crore, primarily due to a 71.70% reduction in the cost of materials consumed and a 29.34% decline in other expenses. Profit before tax slipped 20.38% to Rs 66.80 crore in the first quarter of 2025, compared to Rs 83.90 crore reported in the same period last year. The quarter also saw the successful launch of Allegra D, a new addition to the existing portfolio of Allegra variants in India ' a brand with over 25 years of legacy in the country. The company noted that Q1 2025 and Q1 2024 are not directly comparable due to the demerger and a voluntary product recall of certain key brand variants. Himanshu Bakshi, managing director, Sanofi Consumer Healthcare India, said, 'We continue to focus on strengthening our operations and continue to bring superior, simple and accessible products that enable consumers to control their own health. Our commitment to delivering high-quality, science-backed products remains at the core of our integrated growth strategy.' SCHIL emerged as a distinct legal entity following its demerger from Sanofi India, executed under a Scheme of Arrangement approved by the Mumbai Bench of the National Company Law Tribunal, which became effective on 1 June 2024. This demerger aligns with Sanofi's global strategy, allowing SCHIL to operate independently with a focused mandate in the consumer healthcare sector. Sanofi Consumer Healthcare India is a leading player in India's consumer healthcare market. Leveraging Sanofi's global experience, SCHIL aims to improve consumer well-being through a portfolio spanning allergy, digestive wellness, pain care, multivitamins, and herbal/traditional dietary supplements. Its key brands include Allegra', DePURA', Avil', and Combiflam'. The scrip shed 0.08% to end at Rs 4,938.45 on the BSE on Friday. Powered by Capital Market - Live

Net profit of Sanofi Consumer Healthcare India declined 20.26% to Rs 50.00 crore in the quarter ended March 2025 as against Rs 62.70 crore during the previous quarter ended March 2024. Sales declined 22.11% to Rs 172.60 crore in the quarter ended March 2025 as against Rs 221.60 crore during the previous quarter ended March 2024. ParticularsQuarter EndedMar. 2025Mar. 2024% Var. Sales172.60221.60 -22 OPM %37.0836.91 - PBDT68.8084.80 -19 PBT66.8083.90 -20 NP50.0062.70 -20 Powered by Capital Market - Live

Sanofi Consumer Healthcare India will hold a meeting of the Board of Directors of the Company on 2 May 2025.Powered by Capital Market - Live